186 related articles for article (PubMed ID: 37407064)
1. Effects of volume-based procurement policy on the usage and expenditure of first-generation targeted drugs for non-small cell lung cancer with EGFR mutation in China: an interrupted time series study.
Wang X; Huang H; Sun Y; Zhu Z; Jiang B; Yang L
BMJ Open; 2023 Jul; 13(7):e064199. PubMed ID: 37407064
[TBL] [Abstract][Full Text] [Related]
2. Impact of China's National Volume-Based Procurement on Drug Procurement Price, Volume, and Expenditure: An Interrupted Time Series Analysis in Tianjin.
Zhao B; Wu J
Int J Health Policy Manag; 2023; 12():7724. PubMed ID: 38618801
[TBL] [Abstract][Full Text] [Related]
3. The impact of "4 + 7" volume-based drug procurement on the volume, expenditures, and daily costs of antihypertensive drugs in Shenzhen, China: an interrupted time series analysis.
Yang Y; Tong R; Yin S; Mao L; Xu L; Hao S; Mao Z
BMC Health Serv Res; 2021 Nov; 21(1):1275. PubMed ID: 34823516
[TBL] [Abstract][Full Text] [Related]
4. Impact of National Volume-Based Procurement on the Procurement Volumes and Spending for Antiviral Medications of Hepatitis B Virus.
Yuan J; Lu ZK; Xiong X; Lee TY; Huang H; Jiang B
Front Pharmacol; 2022; 13():842944. PubMed ID: 35734415
[No Abstract] [Full Text] [Related]
5. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
Greenhalgh J; Boland A; Bates V; Vecchio F; Dundar Y; Chaplin M; Green JA
Cochrane Database Syst Rev; 2021 Mar; 3(3):CD010383. PubMed ID: 33734432
[TBL] [Abstract][Full Text] [Related]
6. Trends of Negotiated Targeted Anticancer Medicines Use in China: An Interrupted Time Series Analysis.
Huang C; Ung COL; Wushouer H; Bai L; Li X; Guan X; Shi L
Int J Health Policy Manag; 2022 Aug; 11(8):1489-1495. PubMed ID: 34273922
[TBL] [Abstract][Full Text] [Related]
7. Impacts of national volume-based drug procurement policy on the utilization and costs of antihypertensive drugs in a Chinese medicine hospital: an interrupted time series analysis of 5138 patients.
Shang L; Cheng Y; Zhou J; Bao Y; Kong D; Huang R; Chen Y; Wang H; Gu N; Ma A
Front Pharmacol; 2024; 15():1302154. PubMed ID: 38389928
[No Abstract] [Full Text] [Related]
8. Trends in accessibility of negotiated targeted anti-cancer medicines in Nanjing, China: An interrupted time series analysis.
Liu Y; Yi H; Fang K; Bao Y; Li X
Front Public Health; 2022; 10():942638. PubMed ID: 35937254
[TBL] [Abstract][Full Text] [Related]
9. Effects of removing reimbursement restrictions on targeted therapy accessibility for non-small cell lung cancer treatment in Taiwan: an interrupted time series study.
Hsu JC; Wei CF; Yang SC
BMJ Open; 2019 Mar; 9(3):e022293. PubMed ID: 30878976
[TBL] [Abstract][Full Text] [Related]
10. The impacts of Chinese drug volume-based procurement policy on the use of policy-related antibiotic drugs in Shenzhen, 2018-2019: an interrupted time-series analysis.
Yang Y; Chen L; Ke X; Mao Z; Zheng B
BMC Health Serv Res; 2021 Jul; 21(1):668. PubMed ID: 34238290
[TBL] [Abstract][Full Text] [Related]
11. Impacts of National Drug Price Negotiation on Expenditure, Volume, and Availability of Targeted Anti-Cancer Drugs in China: An Interrupted Time Series Analysis.
Sun Y; Zhu Z; Zhang J; Han P; Qi Y; Wang X; Yang L
Int J Environ Res Public Health; 2022 Apr; 19(8):. PubMed ID: 35457445
[TBL] [Abstract][Full Text] [Related]
12. The impact of the national volume-based procurement policy on the use of policy-related drugs in Nanjing: an interrupted time-series analysis.
Wang X; He X; Zhang P; Zhang M; Ma R; Dai R; Li X
Int J Equity Health; 2023 Sep; 22(1):200. PubMed ID: 37770924
[TBL] [Abstract][Full Text] [Related]
13. Patients' attitudes towards switching to national volume-based procurement (NVBP) Drugs-a qualitative investigation in Wuhan, China.
Tao J; Li S; Xu Q; Gong S; Zeng F
BMC Health Serv Res; 2023 Jan; 23(1):62. PubMed ID: 36670463
[TBL] [Abstract][Full Text] [Related]
14. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
Greenhalgh J; Dwan K; Boland A; Bates V; Vecchio F; Dundar Y; Jain P; Green JA
Cochrane Database Syst Rev; 2016 May; (5):CD010383. PubMed ID: 27223332
[TBL] [Abstract][Full Text] [Related]
15. Impact of the National Centralized Drug Procurement Policy (4 + 7 policy) on the drug expenditures of patients treated in outpatient and emergency departments in a large tertiary level-A hospital in China: A single centre, interrupted time series.
Lan T; Guan L; Pang X; Li X; Yu Q
J Clin Pharm Ther; 2022 Jan; 47(1):104-111. PubMed ID: 34668203
[TBL] [Abstract][Full Text] [Related]
16. Can locally developed me-too drugs aid price negotiation? An example of cancer therapies from China.
Luo Z; Gyawali B; Han S; Shi L; Guan X; Wagner AK
Semin Oncol; 2021 Apr; 48(2):141-144. PubMed ID: 33875231
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness analysis of first-line treatments for advanced epidermal growth factor receptor-mutant non-small cell lung cancer patients.
Li WQ; Li LY; Chai J; Cui JW
Cancer Med; 2021 Mar; 10(6):1964-1974. PubMed ID: 33626238
[TBL] [Abstract][Full Text] [Related]
18. Network meta-analysis of erlotinib, gefitinib, afatinib and icotinib in patients with advanced non-small-cell lung cancer harboring EGFR mutations.
Liang W; Wu X; Fang W; Zhao Y; Yang Y; Hu Z; Xue C; Zhang J; Zhang J; Ma Y; Zhou T; Yan Y; Hou X; Qin T; Dinglin X; Tian Y; Huang P; Huang Y; Zhao H; Zhang L
PLoS One; 2014; 9(2):e85245. PubMed ID: 24533047
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of Osimertinib as First-line Treatment and Sequential Therapy for EGFR Mutation-positive Non-small Cell Lung Cancer in China.
Cai H; Zhang L; Li N; Chen S; Zheng B; Yang J; Weng L; Liu MB
Clin Ther; 2019 Feb; 41(2):280-290. PubMed ID: 30639208
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of icotinib in the treatment of advanced EGFR mutation-positive nonsmall cell lung cancer: A meta-analysis of randomized controlled trials.
Li D; Yao L; Xu L; Li W; Che Y
Medicine (Baltimore); 2022 Dec; 101(48):e32164. PubMed ID: 36482605
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
